Last reviewed · How we verify

Coenzyme Q 10

Universitas Diponegoro · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 5/100

Coenzyme Q 10 is a Small molecule drug developed by Universitas Diponegoro. It is currently FDA-approved. Also known as: CoQ10, ubiquinone.

Coenzyme Q10, also known as Ubiquinone, is being studied as a potential treatment for various conditions, including Non-proliferative Diabetic Retinopathy, Diabetes Mellitus Type 2, Schizophrenia and Related Disorders, Mitochondrial Alteration, and Cognitive Impairment. Clinical trials are investigating the efficacy of Ubiquinone, either alone or in combination with other antioxidants, in addressing these conditions.

At a glance

Generic nameCoenzyme Q 10
Also known asCoQ10, ubiquinone
SponsorUniversitas Diponegoro
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Coenzyme Q 10

What is Coenzyme Q 10?

Coenzyme Q 10 is a Small molecule drug developed by Universitas Diponegoro.

Who makes Coenzyme Q 10?

Coenzyme Q 10 is developed and marketed by Universitas Diponegoro (see full Universitas Diponegoro pipeline at /company/universitas-diponegoro).

Is Coenzyme Q 10 also known as anything else?

Coenzyme Q 10 is also known as CoQ10, ubiquinone.

What development phase is Coenzyme Q 10 in?

Coenzyme Q 10 is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing